NCT05574504 2024-08-01Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline TherapyAdventHealthPhase 2 Withdrawn
NCT03035630 2022-02-15Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell CarcinomaHoosier Cancer Research NetworkPhase 2 Withdrawn
NCT03699384 2019-02-20Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)Memorial Sloan Kettering Cancer CenterPhase 1/2 Withdrawn